Você procurou por: eritropojetin (Maltês - Inglês)

eritropojetin huwa prodott mill- kliewi.
erythropoietin is produced by the kidneys.

taħdem eżattament fl-istess mod bħall-eritropojetin..
it works in exactly the same way as erythropoietin.

kategorija farmakoterapewtika: preparazzjonijiet antianemiċi, eritropojetin kodiċi atc:
antianaemic preparations, erythropoietin atc code:

kategorija farmakoterapewtika: preparazzjonijiet antianemiċi oħra, eritropojetin kodiċi atc: b03xa01
pharmacotherapeutic group: other antianaemic preparations, erythropoietin atc code: b03xa01

kategorija farmakoterapewtika: preparazzjonijiet antianemiċi oħrajn, eritropojetin kodiċi atc: b03xa01
pharmacotherapeutic group: other antianaemic preparations, erythropoietin atc code: b03xa01

aplażja pura ta ’ ċelluli ħomor ikkawżata minn anitkorpi anti- eritropojetin newtralizzanti ġiet im
this has been

epojetin zeta hija kopja tal-proteina umana eritropojetin u taġixxi bl-istess mod.
epoetin zeta is a copy of the human protein erythropoietin and acts in the same way.

il-massa molekulari apparenti ta’ eritropojetin hija ta’ 32 000-40 000 dalton.
the apparent molecular weight of erythropoietin is 32 000-40 000 dalton.

b’riżultat ta’ dan, mircera jista’ jingħata inqas spiss minn eritropojetin naturali.
as a result, mircera can be given less often than natural erythropoietin.

bħal fatturi oħra ta’ tkabbir ematopojetiku, l-eritropojetin wera in vitro propretajiet stimulanti fuq ċelluli endoteljali.
as with other haematopoietic growth factors, erythropoietin has shown in vitro stimulating properties on human endothelial cells.

l-azzjonjiet ċitotossiċi tal-eritropojetin fuq iċ-ċelluli tal-mudullun ma setgħux jiġu osservati.
cytotoxic actions of erythropoietin on bone marrow cells could not be detected.

97 rapporti konflittwali fil- letteratura dwar jekk l- eritropojetin jistax ikollu rwol ewlieni bħala proliferatur ta ’ tumuri.
there are conflicting reports in the literature regarding whether erythropoietin may play a major role as tumour proliferator.

ir-riċettaturi tal-eritropojetin jistgħu jiġu espressi fuq il-wiċċ ta’ diversi ċelluli ta’ tumuri.
erythropoietin receptors may be expressed on the surface of a variety of tumour cells.

ma teżistix evidenza li tindika li t-trattament bl-eritropojetin ibiddel il-metaboliżmu ta’ prodotti mediċinali oħra.
there is no evidence to indicate that treatment with erythropoietin alters the metabolism of other medicinal products.

in-nuqqas ta’ rispons għat-terapija bl-eritropojetin għandu iwassal għal tfitxxija ta’ fatturi kawżattivi.
non response to erythropoietin therapy should prompt a search for causative factors.

aplażja pura ta’ ċelluli ħomor ikkawżata minn anitkorpi anti-eritropojetin newtraliżanti ġiet irrappurtataf’assoċjazzjoni ma’ esas, inkluż aranesp.
pure red cell aplasia caused by neutralising anti-erythropoietin antibodies has been reported in association with esas, including aranesp.

ir- riċetturi ta' eritropojetin jistgħu jkunu espressi fuq il-wiċċ ta' varjetà ta' ċelluli ta' tumur.
erythropoietin receptors may be expressed on the surface of a variety of tumour cells.

indipendentament mit-trattament bl-eritropojetin, episodji trombotiċi u vaskulari jistgħu jseħħu f’pazjenti kirurġiċi b’mard kardjovaskulari wara flebotomija ripetuta.
independent of erythropoietin treatment, thrombotic and vascular events may occur in surgical patients with underlying cardiovascular disease following repeated phlebotomy.

l- efikaċija bijoloġika tal- eritropojetin intweriet f’ diversi mudelli ta ’ l- annimali in vivo (ġrieden normali u anemiċi, ġrieden polycythaemic).
23 the biological efficacy of erythropoietin has been demonstrated in various animal models in vivo (normal and anaemic rats, polycythaemic mice).